-
methyl(3-{tetracyclo[6.6.2.02,7.09,14]hexadeca-2(7),3,5,9(14),10,12-hexaen-1-yl}propyl)amine hydrochloride
-
ChemBase ID:
73059
-
Molecular Formular:
C20H24ClN
-
Molecular Mass:
313.86426
-
Monoisotopic Mass:
313.15972745
-
SMILES and InChIs
SMILES:
c1ccc2c(c1)C1(c3c(C2CC1)cccc3)CCCNC.Cl
Canonical SMILES:
CNCCCC12CCC(c3c1cccc3)c1c2cccc1.Cl
InChI:
InChI=1S/C20H23N.ClH/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20;/h2-5,7-10,15,21H,6,11-14H2,1H3;1H
InChIKey:
NZDMFGKECODQRY-UHFFFAOYSA-N
-
Cite this record
CBID:73059 http://www.chembase.cn/molecule-73059.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
methyl(3-{tetracyclo[6.6.2.02,7.09,14]hexadeca-2(7),3,5,9(14),10,12-hexaen-1-yl}propyl)amine hydrochloride
|
methyl(3-{tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaen-1-yl}propyl)amine hydrochloride
|
|
|
IUPAC Traditional name
|
maprotiline hydrochloride
|
methyl(3-{tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaen-1-yl}propyl)amine hydrochloride
|
|
|
Synonyms
|
3-(9,10-dihydro-9,10-ethanoanthracen-9-yl)-N-methylpropan-1-amine hydrochloride
|
Deprilept
|
Ludiomil
|
Psymion
|
Maprotiline hydrochloride
|
9-(γ-Methylaminopropyl)-9,10-dihydro-9,10-ethanoanthracene hydrochloride
|
Maprotiline hydrochloride
|
|
|
CAS Number
|
|
EC Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
H Acceptors
|
1
|
H Donor
|
1
|
LogD (pH = 5.5)
|
1.1368963
|
LogD (pH = 7.4)
|
1.4832375
|
Log P
|
4.3721046
|
Molar Refractivity
|
99.3017 cm3
|
Polarizability
|
34.660324 Å3
|
Polar Surface Area
|
12.03 Å2
|
Rotatable Bonds
|
4
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Selleck Chemicals
Sigma Aldrich
Selleck Chemicals -
S2517
|
Research Area: Neurological Disease Biological Activity: Maprotiline hydrochloride (Deprilept, Ludiomil, Psymion) is a selective noradrenalin re-uptake inhibitor and a tetracyclic antidepressant. Maprotiline hydrochloride (Deprilept, Ludiomil, Psymion) acts primarily by potentiation of central adrenergic synapses by blocking reuptake of norepinephrine at nerve endings. The pharmacologic action of Maprotiline hydrochloride (Deprilept, Ludiomil, Psymion) is thought to be responsible for the drug’s antidepressant and anxiolytic effects. Maprotiline hydrochloride (Deprilept, Ludiomil, Psymion) is indicated for the treatment of depressive illness in patients with depressive neurosis (dysthymic disorder) and manic-depressive illness, depressed type (major depressive disorder). Maprotiline hydrochloride (Deprilept, Ludiomil, Psymion) is also effective for the relief of anxiety associated with depression. [1][2] |
PATENTS
PATENTS
PubChem Patent
Google Patent